The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders

Citations Over TimeTop 10% of 2020 papers

Abstract

Fractalkine (FKN, CX3CL1) is a transmembrane chemokine expressed by neurons in the central nervous system (CNS). CX3CL1 signals through its unique receptor, CX3CR1, that is expressed in microglia. Within the CNS, fractalkine acts as a regulator of microglia activation in response to brain injury or inflammation. During the last decade, there has been a growing interest in the roles that the CX3CL1/CX3CR1 signaling pathway plays in the neuropathology of a diverse array of brain disorders. However, the reported results have proven controversial, indicating that a disruption of the CX3CL1 axis induces a disease-specific microglial response that may have either beneficial or detrimental effects. Therefore, it has become clear that the understanding of neuron-to-glia signals mediated by CX3CL1/CX3CR1 at different stages of diseases could provide new insight into potential therapeutic targets. Hence, the aim of this review is to provide a summary of the literature on the emerging role of CX3CL1 in animal models of some brain disorders.

Related Papers

• → CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival(2008)479 cited
• → CX3CR1 in Microglia Regulates Brain Amyloid Deposition through Selective Protofibrillar Amyloid-β Phagocytosis(2010)267 cited
• → A20 critically controls microglia activation and inhibits inflammasome-dependent neuroinflammation(2018)236 cited
• → Differential Regional Vulnerability of the Brain to Mild Neuroinflammation Induced by Systemic LPS Treatment in Mice(2022)24 cited
• → Alzheimer’s Disease Research Using Human Microglia(2019)26 cited